ReviewJournal of medicinal chemistry2025
Prodrugs Targeting Prostate-Specific Membrane Antigen against Prostate Cancer.
Review in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Design, synthesis, and anti-prostate cancer activity evaluation of novel thieno[2,3-b]pyridine derivatives as potential BLM helicase inhibitors.Molecular diversity · 2026Article
- A Review of Approaches to the Synthesis of DCL-Based Prostate-Specific Membrane Antigen Ligands.International journal of molecular sciences · 2026Review
- A PSMA-targeted dextran-based conjugate eradicates PSMA-overexpressing prostate tumors while abolishing cabazitaxel toxicity.Theranostics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific membrane antigen (PSMA) or glutamate carboxypeptidase II (GCPII) is a promising target for metastatic castration-resistant prostate cancer (mCRPC) due to its high expression in prostate cancer cell membranes and low expression in normal tissues. Ligand-targeted drugs (LTDs) targeting PSMA are gaining popularity for their high affinity, specificity, and ease of synthesis. LTDs consist of a small molecule targeting PSMA and carrying the cytotoxic agent to the cancer cells, which is then released through a cleavable linker (enzymatically or chemically cleaved) into the tumor tissue. Several PSMA-targeting LTDs have demonstrated promising results in both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.